search

Results first in English | All languages
Restrict:

Results 1 - 19 of 19 for "Debiopharm". [0.01 sec.]

Directory
Pharmacology
Debiopharm
Debiopharm ... Debiopharm Location: Lausanne - Lake Geneva region Chemin
News - 15 Dec 2021
Health - Pharmacology
Effective combination cancer treatment
Michal Grzmil from the Centre for Radiopharmaceutical Sciences wants to improve the subject of clinical trials conducted in close collaboration Debiopharm International, a drug company based in Lausanne, and University...
Short news - 1 Nov 2018
Health - Materials Science
Lifting the maskrespiratory activity. Back in 2016, the team received the Challenge Debiopharm-Inartis Award. The project, which is also funded by the Gebert Rüf...
News - 1 May 2018
Pharmacology - Chemistry
Worms in high-tech housing replace laboratory micetoxicity," adds Robert Mader, in charge of toxicological studies at Debiopharm. The objective is to select the molecule with the fewest side effects...
Short news - 26 Oct 2016
Innovation
A 10 million euro round of financing for the start up Coorpacademy
to bring in 10 million euros from Serena Capital, NextStage and Debiopharm Investment. Coorpacademy was launched by three successful...
Job Offer - 19 Dec 2013 [archive] - Debiopharm - Lausanne
Health - Life Sciences
Medical Director, Infectiology - Auto-Immune DeseasesDebiopharm Group? (Debiopharm) is a Swiss-based biopharmaceutical group of companies with a focus
Job Offer - 23 Aug 2012 [archive] - Debiopharm - Lausanne
Health
Medical Director, OncologyDebiopharm Group? (Debiopharm) is a Swiss-based biopharmaceutical group of companies with a focus
Job Offer - 23 Aug 2012 [archive] - Debiopharm - Lausanne
Health
Medical Director, Internal MedicineDebiopharm Group? (Debiopharm) is a Swiss-based biopharmaceutical group of companies with a focus
Job Offer - 2 Apr 2012 [archive] - Debiopharm - Lausanne
Health - Life Sciences
Medical Director OncologyDebiopharm Group? (Debiopharm) is a Swiss-based biopharmaceutical group of companies with a focus
Job Offer - 15 Mar 2012 [archive] - Debiopharm - Lausanne
Health - Life Sciences
PROJECT MANAGER, Business Unit DiagnosticsDebiopharm Group? is a Swiss-based biopharmaceutical group of companies with a
Short news - 13 Mar 2012
Health
The registrations to the "LSS2012" are open
© 2012 EPFL interventions. The LSS2012 will also be the occasion, for the DebioPharm Group, to present the Debiopharm Awards 2012 . Applications are...
Short news - 8 Dec 2011
Health - Life Sciences
Nipping metastases in the bud
Breast cancer cells (green) find their niche in a periostin (red) micro-environm metastases develop," explains Joerg Huelsken, holder of the EPFL Debiopharm Chair in Signal Transduction in Oncogenesis. "Without this protein,...
Short news - 5 Nov 2011
Health - Pharmacology
Novartis DEB025 data showed viral clearance as early as six weeks and potential for interferon-free therapy in hepatitis C patientsgenotype 1 experienced patients. Novartis licensed DEB025 from Debiopharm Group TM , an independent biopharmaceuticals company based in...
Short news - 5 Sep 2011
Health
Cancer understanding an elusive Diseaseto achieve this - various forms of mutations or alterations". Debiopharm, a partner in the event, will present its Life Science Award 2011 on...
Short news - 31 Mar 2011
Pharmacology - Health
Novartis first-in-class antiviral DEB025 achieved sustained viral response in 76% of patients with chronic hepatitis C, new phase II study showsand G3 treatment-naive patients. Novartis in-licensed DEB025 from Debiopharm Group(TM), an independent biopharmaceuticals company based in...
Job Offer - 17 Mar 2011 [archive] - Debiopharm - Lausanne
Life Sciences - Health
Project Manager expérimenté(e)Debiopharm Group ? (Debiopharm) est un groupe de Sociétés biopharmaceutiques basé en Suisse qui met
Job Offer - 4 Mar 2011 [archive] - Debiopharm - Lausanne
Health - Life Sciences
Head of Evaluation - Internal MedicineDebiopharm Group? (Debiopharm) is a Swiss-based biopharmaceutical group of companies with a focus
Short news - 9 Feb 2010
Pharmacology
Novartis gains exclusive rights to Debio 025, an antiviral agent in Phase IIb development as potential first-in-class hepatitis C therapyof care for the disease. Debio 025 has been in-licensed from Debiopharm Group (TM) , an independent biopharmaceuticals company based in...
News - 29 Feb 2008
Health - Life Sciences
La lutte contre le cancer et plus particulièrement contre les métastases s'intensifieLe jeune professeur Jörg Huelsken dirigera la chaire Debiopharm à l'EPFL. Il y développera son travail de recherche sur les mécanismes fondamentaux qui dictent la réplication de certaines cellules impliquées dans le cancer.